Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.44 |
| ▸ | NSD2 | O96028 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694209 | 0.84 | GSK3B (0.61) | GSK3BNSD3NSD2LMNASMN1; SMN2 | |
| SCHEMBL16401839 | 0.78 | MEN1 (0.51) | FKBP1ALMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL29274097 | 0.75 | GSK3B (0.73) | GSK3BADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL9393670 | 0.72 | GSK3B (0.69) | GSK3BADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL16401569 | 0.71 | FKBP1A (0.49) | FKBP1AMEN1KMT2AALDH1A1 | |
| SCHEMBL14637667 | 0.71 | GSK3B (0.59) | GSK3BADORA2AADORA1ALDH1A1AHCY | |
| SCHEMBL6046938 | 0.70 | PI4KA (0.59) | GSK3BNSD3LMNASMN1; SMN2ADORA2A | |
| SCHEMBL3630349 | 0.70 | GSK3B (0.65) | GSK3BADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL27352120 | 0.70 | GSK3B (0.69) | GSK3BADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL23869745 | 0.70 | PI4KA (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | claimed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | claimed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, FBP1, PNKP | GSK3B 3925/4885FKBP1A 3387/4885NSD3 2352/4885 |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | GSK3B 3498/4885FKBP1A 3913/4885NSD3 3552/4885 |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, TYMP, PAICS | GSK3B 3498/4885FKBP1A 3913/4885NSD3 3552/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | GSK3B 3498/4885FKBP1A 3913/4885NSD3 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.